Next‐Generation Model‐Based Drug Discovery and Development: Quantitative and Systems Pharmacology

Pharmaceutical researchers have undertaken many initiatives and technologies to stem the rising costs of drug discovery and development. Biomarkers, adaptive trial designs, modeling, trial simulations, predictive metabolism, data mining, and disease models have reshaped the way in which researchers approach discovery and development. Quantitative pharmacology (QP), which leverages model‐based approaches, operates at both cultural and technical levels to integrate data and scientific disciplines so as to utilize existing knowledge while concomitantly enhancing the ability to make predictions about future experiments and results.

[1]  Marc Pfister,et al.  Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development , 2008, The AAPS Journal.

[2]  Lawrence J Lesko,et al.  Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.

[3]  D. Noble,et al.  The heart is already working. , 2005, Biochemical Society transactions.

[4]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[5]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[6]  Vikram Sinha,et al.  Model-Based Drug Development: The Road to Quantitative Pharmacology , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  Jvs Gobburu Biomarkers in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.